^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XMT-1592

    i
    Other names: XMT-1592, XMT1592, XMT 1592
    Company:
    Mersana, Recepta
    Drug class:
    Microtubule inhibitor, NaPi2b-targeted antibody-drug conjugate
    Related drugs:
    8ms
    First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov)
    P1, N=31, Terminated, Mersana Therapeutics | Phase classification: P1b --> P1
    Phase classification
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    XMT-1592
    1year
    First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov)
    P1b, N=31, Terminated, Mersana Therapeutics | N=120 --> 31 | Active, not recruiting --> Terminated; discontinued development program
    Enrollment change • Trial termination
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    XMT-1592
    almost2years
    First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov)
    P1b, N=120, Active, not recruiting, Mersana Therapeutics | Trial primary completion date: Dec 2022 --> Mar 2023
    Trial primary completion date
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    XMT-1592
    over2years
    First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov)
    P1b, N=120, Active, not recruiting, Mersana Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    XMT-1592
    3years
    Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. (PubMed, Biochem Biophys Rep)
    The sodium-dependent phosphate transporter NaPi2b encoded by SLC34A2 gene is expressed in 80-90% of epithelial ovarian cancers and used as a target for therapeutic antibodies XMT-1536, and XMT-1592, which are derived from MX35 antibodies and used in clinical trials for the treatment of ovarian and lung cancers. In this work, we demonstrated that the expression of the human NaPi2b (hNaPi2b) transporter is downregulated in the tumors of patients receiving neoadjuvant therapy and during the development of disease. The data suggest that the level of expression of the SLC34A2 gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.
    Journal
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    SLC34A2 expression
    |
    upifitamab rilsodotin (XMT-1536) • XMT-1592
    over3years
    First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov)
    P1b, N=120, Recruiting, Mersana Therapeutics | Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Mar 2021 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    XMT-1592